Transitioning between views
Loading the next view
Pulling the latest page data and restoring the context around your last step.
Still working on it — slow network or a cold server. You can wait, or refresh.
Pulling the latest page data and restoring the context around your last step.
Still working on it — slow network or a cold server. You can wait, or refresh.
Pulling stage timeline, price chart, and scan history…
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Visit company website →All analytics based on EOD data. Data as of 2026-06-25. Past data patterns are not indicative of future results. This page is a data analytics tool only.